Moclobemide
As of the edition of 20 October 2026, Moclobemide is a small molecule: marketed, first approved in 1990 (FR); acts on MAOA.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1992
- Kind
- Small molecule
- Brand name
- Moclamine
- First approved
- 12 September 1990 (FR)
- Approvals on record
- 4 in 3 regions
- Holder of the most recent approval
- Bausch Health; 3 holders in all
- Registered trials
- 3, 2 stopped early
- Disease areas
- Mental health; Chemically induced; Nervous system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| MAOA | Amine oxidase [flavin-containing] A | P21397 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 2 | 1 | 0 | 1 |
| Phase 3 | 1 | 0 | 0 | 1 |
| All trials | 3 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Bausch Health | Acquired holder | 1992 to now |